Nicolet Advisory Services LLC Purchases 815 Shares of Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson logo

Nicolet Advisory Services LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 10.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,336 shares of the company’s stock after acquiring an additional 815 shares during the period. Nicolet Advisory Services LLC’s holdings in Johnson & Johnson were worth $1,337,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. RKL Wealth Management LLC lifted its position in shares of Johnson & Johnson by 2.1% during the second quarter. RKL Wealth Management LLC now owns 48,233 shares of the company’s stock worth $8,562,000 after acquiring an additional 1,010 shares in the last quarter. Geller Advisors LLC raised its position in shares of Johnson & Johnson by 7.5% in the second quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock worth $1,644,000 after buying an additional 648 shares in the last quarter. Simon Quick Advisors LLC raised its position in shares of Johnson & Johnson by 296.9% in the second quarter. Simon Quick Advisors LLC now owns 8,739 shares of the company’s stock worth $1,495,000 after buying an additional 6,537 shares in the last quarter. Lokken Investment Group LLC raised its position in shares of Johnson & Johnson by 1.6% in the second quarter. Lokken Investment Group LLC now owns 12,968 shares of the company’s stock worth $2,302,000 after buying an additional 201 shares in the last quarter. Finally, Keebeck Alpha LP raised its position in shares of Johnson & Johnson by 13.4% in the second quarter. Keebeck Alpha LP now owns 4,442 shares of the company’s stock worth $788,000 after buying an additional 525 shares in the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on JNJ. Atlantic Securities increased their target price on Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a research note on Wednesday, January 25th. Credit Suisse Group assumed coverage on Johnson & Johnson in a research note on Thursday, November 17th. They set a “neutral” rating and a $170.00 price objective on the stock. Citigroup raised their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, December 12th. Morgan Stanley raised their target price on Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 25th. Finally, Raymond James cut their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 19th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $175.71.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares in the company, valued at approximately $6,431,835.20. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares in the company, valued at approximately $6,431,835.20. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Jennifer L. Taubert sold 76,923 shares of the business’s stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares in the company, valued at approximately $22,354,891.68. The disclosure for this sale can be found here. In the last quarter, insiders have sold 181,955 shares of company stock worth $32,081,502. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Trading Down 0.4 %

NYSE:JNJ opened at $162.04 on Wednesday. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The company has a market cap of $423.65 billion, a PE ratio of 24.04, a price-to-earnings-growth ratio of 2.79 and a beta of 0.54. The company has a 50 day simple moving average of $172.25 and a two-hundred day simple moving average of $170.03.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.94%. The firm had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. During the same quarter in the previous year, the firm posted $2.13 EPS. The company’s revenue for the quarter was down 4.4% compared to the same quarter last year. Research analysts forecast that Johnson & Johnson will post 10.5 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.79%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is 67.06%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.